May 9 |
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates
|
May 9 |
Kronos Bio Reports First-Quarter 2024 Financial Results
|
May 6 |
Kronos Bio: Underestimated Drug Discovery Platform
|
May 6 |
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
|
Apr 24 |
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
Mar 27 |
Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?
|
Mar 21 |
Kronos Bio reports Q4 results
|
Mar 21 |
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
|
Mar 7 |
Kronos cuts 21% of workforce, extends cash runway into 2H 2026
|
Mar 7 |
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
|